Trimedyne Cleared to Sell Laser Needle
- Share via
<i> Dow Jones</i>
Trimedyne Inc. said Thursday it has received regulatory clearance to begin marketing a new laser needle used in treating herniated lumbar disks.
The Irvine company’s shares moved up $1.22 to $2.59 after the announcement.
The company said its OmniTip side-firing laser needle received clearance from the Food and Drug Administration. The device vaporizes a portion of a herniated lumbar spinal disk in a minimally invasive procedure, reducing the volume of the disk.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
